Under one in 10 individuals eligible to benefit from obesity jabs like Wegovy have access to them, caution the WHO as it releases its initial guidance on the medications.
Given more than one billion individuals worldwide now obese, it is advocating for more widespread and fairer access to this class of drugs.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The latest guidelines acknowledges that obesity is a chronic disease that can be treated with holistic and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant obstacles to widespread availability to the injections that can aid individuals in losing substantial weight, notes the organization.
GLP-1 Therapy Supply Crisis
Even under the present most optimistic scenario, the supply of such drugs would only suffice for approximately 100 million people – less than 10% of the global need, according to the WHO.
The guideline encourages governments and firms to increase access, via approaches like patent sharing.
Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
How Weight-Loss Jabs Function
The injections replicate a body's own hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so users eat less.
Individuals commonly see weight reduction after several weeks of beginning the weekly injections.
Evidence points to patients may see weight return within a year of stopping the drug, when their usual hunger return.
Being above a healthy weight elevates your likelihood for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
